

Michele W L Teng

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8084580/michele-w-l-teng-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

112
papers

12,319
citations

56
h-index

110
g-index

129
ext. papers

15,189
ext. citations

11.9
avg, IF

6.78
L-index

#	Paper	IF	Citations
112	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015 , 75, 2139-45	10.1	864
111	Translational biology of osteosarcoma. <i>Nature Reviews Cancer</i> , 2014 , 14, 722-35	31.3	644
110	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 143-58	19.4	561
109	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 151-167	19.4	518
108	IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. <i>Nature Medicine</i> , 2015 , 21, 719-29	50.5	488
107	Anti-TIM3 antibody promotes T cell IFN- γ -mediated antitumor immunity and suppresses established tumors. <i>Cancer Research</i> , 2011 , 71, 3540-51	10.1	396
106	De-novo and acquired resistance to immune checkpoint targeting. <i>Lancet Oncology</i> , 2017 , 18, e731-e741	27.1	383
105	Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. <i>Cancer Discovery</i> , 2016 , 6, 1382-1399	24.4	356
104	Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 7142-7	11.5	334
103	Tumor immuno-evasion by the conversion of effector NK cells into type 1 innate lymphoid cells. <i>Nature Immunology</i> , 2017 , 18, 1004-1015	19.1	330
102	CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. <i>Journal of Immunology</i> , 2006 , 176, 1582-7	5.3	323
101	TIGIT predominantly regulates the immune response via regulatory T cells. <i>Journal of Clinical Investigation</i> , 2015 , 125, 4053-62	15.9	317
100	Resistance to PD1/PDL1 checkpoint inhibition. <i>Cancer Treatment Reviews</i> , 2017 , 52, 71-81	14.4	305
99	Targeting immunosuppressive adenosine in cancer. <i>Nature Reviews Cancer</i> , 2017 , 17, 709-724	31.3	304
98	CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. <i>Cancer Research</i> , 2011 , 71, 2892-900	10.1	297
97	Cancer immunoediting by the innate immune system in the absence of adaptive immunity. <i>Journal of Experimental Medicine</i> , 2012 , 209, 1869-82	16.6	221
96	Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. <i>Cancer Cell</i> , 2016 , 30, 391-403	24.3	216

95	Immune-mediated dormancy: an equilibrium with cancer. <i>Journal of Leukocyte Biology</i> , 2008 , 84, 988-93	6.5	205
94	Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. <i>Cancer Research</i> , 2010 , 70, 7788-99	10.1	201
93	TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. <i>OncImmunology</i> , 2013 , 2, e23849	7.2	193
92	From mice to humans: developments in cancer immunoediting. <i>Journal of Clinical Investigation</i> , 2015 , 125, 3338-46	15.9	188
91	Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. <i>Cancer Research</i> , 2014 , 74, 3652-8	10.1	178
90	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018 , 48, 91-103	12.7	164
89	Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. <i>Cancer Research</i> , 2010 , 70, 7800-9	10.1	153
88	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2016 , 6, 446-59	24.4	147
87	Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. <i>Immunity</i> , 2017 , 47, 789-802.e9	32.3	142
86	Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. <i>Blood</i> , 2002 , 100, 3155-63	2.2	142
85	TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma. <i>Blood</i> , 2018 , 132, 1689-1694	2.2	131
84	Supernatural T cells: genetic modification of T cells for cancer therapy. <i>Nature Reviews Immunology</i> , 2005 , 5, 928-40	36.5	129
83	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 5183-5188	12.9	127
82	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015 , 25, 208-24	24.7	126
81	Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 19051-6	11.5	124
80	IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 8328-33	11.5	101
79	Prospects for TIM3-Targeted Antitumor Immunotherapy. <i>Cancer Research</i> , 2011 , 71, 6567-71	10.1	99
78	CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. <i>Cancer Research</i> , 2014 , 74, 436-45	10.1	90

77	Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 4141-6	11.5	88
76	Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. <i>Journal of Immunology</i> , 2002 , 169, 5780-6	5.3	87
75	Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity. <i>Cancer Discovery</i> , 2019 , 9, 1754-1773	24.4	86
74	A balance of interleukin-12 and -23 in cancer. <i>Trends in Immunology</i> , 2013 , 34, 548-55	14.4	85
73	Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. <i>Molecular Therapy</i> , 2014 , 22, 18-27	11.7	83
72	Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection. <i>Blood</i> , 2005 , 106, 2995-3003	2.2	82
71	Tc17 cells are a proinflammatory, plastic lineage of pathogenic CD8+ T cells that induce GVHD without antileukemic effects. <i>Blood</i> , 2015 , 126, 1609-20	2.2	78
70	Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. <i>Cancer Research</i> , 2012 , 72, 3987-96	10.1	76
69	The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment. <i>Clinical Cancer Research</i> , 2019 , 25, 5743-5751	12.9	73
68	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. <i>Clinical Cancer Research</i> , 2017 , 23, 2478-2490	12.9	71
67	Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. <i>Journal of Immunology</i> , 2010 , 184, 5493-501	5.3	70
66	Donor colonic CD103+ dendritic cells determine the severity of acute graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2015 , 212, 1303-21	16.6	69
65	Immunosurveillance and therapy of multiple myeloma are CD226 dependent. <i>Journal of Clinical Investigation</i> , 2015 , 125, 2077-89	15.9	69
64	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. <i>Journal of Clinical Investigation</i> , 2018 , 128, 2613-2625	15.9	66
63	Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. <i>Journal of Immunology</i> , 2004 , 173, 2143-50	5.3	65
62	Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. <i>Cancer Research</i> , 2010 , 70, 2665-74	10.1	62
61	Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer. <i>Cancer Research</i> , 2016 , 76, 5288-301	10.1	59
60	Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018 , 10,	10.2	58

59	Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor. <i>Cancer Research</i> , 2016 , 76, 6266-6277	10.1	57
58	Combined natural killer T-cell based immunotherapy eradicates established tumors in mice. <i>Cancer Research</i> , 2007 , 67, 7495-504	10.1	57
57	Gene modification strategies to induce tumor immunity. <i>Immunity</i> , 2005 , 22, 403-14	32.3	52
56	A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. <i>Cancer Gene Therapy</i> , 2004 , 11, 371-9	5.4	51
55	MAIT Cells Promote Tumor Initiation, Growth, and Metastases via Tumor MR1. <i>Cancer Discovery</i> , 2020 , 10, 124-141	24.4	50
54	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. <i>Clinical and Translational Immunology</i> , 2014 , 3, e22	6.8	48
53	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. <i>Clinical Cancer Research</i> , 2017 , 23, 5789-5801	12.9	47
52	Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 676-693	19.4	46
51	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. <i>Onc Immunology</i> , 2018 , 7, e1431088	7.2	45
50	Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. <i>Human Gene Therapy</i> , 2004 , 15, 699-708	4.8	43
49	CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function. <i>Cancer Immunology Research</i> , 2019 , 7, 559-571	12.5	41
48	Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?. <i>Genome Medicine</i> , 2016 , 8, 111	14.4	40
47	IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection. <i>Science Immunology</i> , 2019 , 4,	28	39
46	The role of NK cells and CD39 in the immunological control of tumor metastases. <i>Onc Immunology</i> , 2019 , 8, e1593809	7.2	38
45	Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. <i>Cancer Research</i> , 2011 , 71, 2077-86	10.1	38
44	Autophagy-dependent regulatory T cells are critical for the control of graft-versus-host disease. <i>JCI Insight</i> , 2016 , 1, e86850	9.9	33
43	Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. <i>Onc Immunology</i> , 2019 , 8, e1581530	7.2	31
42	Control of Metastases via Myeloid CD39 and NK Cell Effector Function. <i>Cancer Immunology Research</i> , 2020 , 8, 356-367	12.5	31

41	Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases. <i>Cancer Research</i> , 2014 , 74, 2412-21	10.1	29
40	Cytotoxic lymphocytes; instigators of dramatic target cell death. <i>Biochemical Pharmacology</i> , 2004 , 68, 1033-40	6	28
39	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020 , 26, 3671-3681	12.9	27
38	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. <i>Onc Immunology</i> , 2018 , 7, e1424677	7.2	27
37	Biology and clinical observations of regulatory T cells in cancer immunology. <i>Current Topics in Microbiology and Immunology</i> , 2011 , 344, 61-95	3.3	27
36	Does IL-17 suppress tumor growth?. <i>Blood</i> , 2010 , 115, 2554-5; author reply 2556-7	2.2	25
35	Role of IL-17 and IL-22 in autoimmunity and cancer. <i>Actas Dermo-sifiliograficas</i> , 2014 , 105 Suppl 1, 41-50	0.5	24
34	CD1d activation and blockade: a new antitumor strategy. <i>Journal of Immunology</i> , 2009 , 182, 3366-71	5.3	24
33	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. <i>Nature Immunology</i> , 2020 , 21, 1205-1218	19.1	24
32	Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT. <i>Blood Advances</i> , 2017 , 1, 341-351	7.8	23
31	Targeting regulatory T cells in tumor immunotherapy. <i>Immunology and Cell Biology</i> , 2014 , 92, 473-4	5	23
30	Stable IL-10: a new therapeutic that promotes tumor immunity. <i>Cancer Cell</i> , 2011 , 20, 691-3	24.3	23
29	CD1d-based combination therapy eradicates established tumors in mice. <i>Journal of Immunology</i> , 2009 , 183, 1911-20	5.3	22
28	Interleukin 21 enhances antibody-mediated tumor rejection. <i>Cancer Research</i> , 2008 , 68, 3019-25	10.1	22
27	Antitumor activity of dual-specific T cells and influenza virus. <i>Cancer Gene Therapy</i> , 2007 , 14, 499-508	5.4	21
26	Batf3 DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy. <i>Onc Immunology</i> , 2019 , 8, e1546068	7.2	20
25	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. <i>Onc Immunology</i> , 2018 , 7, e1445949	7.2	19
24	Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy. <i>Human Gene Therapy</i> , 2006 , 17, 1134-43	4.8	19

23	Co-blockade of immune checkpoints and adenosine A receptor suppresses metastasis. <i>Oncolimmunology</i> , 2014 , 3, e958952	7.2	18
22	Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. <i>Oncolimmunology</i> , 2017 , 6, e1312044	7.2	15
21	Both IFN- γ and IL-17 are required for the development of severe autoimmune gastritis. <i>European Journal of Immunology</i> , 2012 , 42, 2574-83	6.1	15
20	Infiltrating Myeloid Cells Drive Osteosarcoma Progression via GRM4 Regulation of IL23. <i>Cancer Discovery</i> , 2019 , 9, 1511-1519	24.4	13
19	Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model. <i>JCI Insight</i> , 2019 , 5,	9.9	11
18	T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner. <i>Journal of Biological Chemistry</i> , 2005 , 280, 38235-41	5.4	10
17	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). <i>Trials</i> , 2019 , 20, 753	2.8	10
16	Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23. <i>Cancer Immunology Research</i> , 2018 , 6, 978-987	12.5	9
15	Cancer. Can cancer trigger autoimmunity?. <i>Science</i> , 2014 , 343, 147-8	33.3	8
14	The interaction between murine melanoma and the immune system reveals that prolonged responses predispose for autoimmunity. <i>Oncolimmunology</i> , 2013 , 2, e23036	7.2	8
13	Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors. <i>Oncolimmunology</i> , 2014 , 3, e963395	7.2	7
12	Checkpoint Immunotherapy: Picking a Winner. <i>Cancer Discovery</i> , 2016 , 6, 818-20	24.4	7
11	Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression. <i>Oncolimmunology</i> , 2014 , 3, e28964	7.2	6
10	Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy 2020 , 8,		6
9	IL-23 promotes the development of castration-resistant prostate cancer. <i>Immunology and Cell Biology</i> , 2018 , 96, 883-885	5	4
8	Cancer Immunoediting 2013 , 85-99		3
7	ROCK2 inhibition attenuates profibrogenic immune cell function to reverse thioacetamide-induced liver fibrosis.. <i>JHEP Reports</i> , 2022 , 4, 100386	10.3	3
6	A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and Immunotherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. <i>Radiation Oncology</i> , 2021 , 16, 69	4.2	3

5	Systemic administration of IL-33 induces a population of circulating KLRG1 type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma. <i>Immunology and Cell Biology</i> , 2021 , 99, 65-83	5	3
4	Purinergic Receptors: Novel Targets for Cancer Immunotherapy 2018 , 115-141		2
3	Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors.. <i>Science Translational Medicine</i> , 2022 , 14, eabj9779	17.5	2
2	Adoptive Transfer of Chimeric Fc γ RI Gene-Modified Human T Cells for Cancer Immunotherapy. <i>Human Gene Therapy</i> , 2006 , 061019064400001	4.8	
1	Preoperative PD1 checkpoint blockade and receptor activator of NF κ B ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS129-TPS129	2.2	